🇺🇸 FDA
Pipeline program

EIK1005 10mg Tablets, EIK1005 50mg Tablets, PEMBROLIZUMAB , EIK1005 200mg Tablets

EIK1005-002

Phase 2 small_molecule active

Quick answer

EIK1005 10mg Tablets, EIK1005 50mg Tablets, PEMBROLIZUMAB , EIK1005 200mg Tablets for Advanced Solid Tumors is a Phase 2 program (small_molecule) at Eikon Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Eikon Therapeutics
Indication
Advanced Solid Tumors
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials